| Filed On | Filing |
|---|---|
| 12 Nov 2026 | Form 4 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 | SCHEDULE 13D/A |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 |
| 09 Nov 2026 |
Form 4: Goldentree Asset Management Lp, 10% owner and 2 others
Bought 145,716 shares ($13M) · Bought 150,000 shares ($13.4M) |
| 16 Oct 2026 |
Form 4: Goldentree Asset Management Lp, 10% owner and 2 others
Bought 137,000 shares ($12.3M) |
| 06 Oct 2026 |
Form 4: Goldentree Asset Management Lp, 10% owner and 2 others
Bought 463,000 shares ($42.1M) |
| 06 Oct 2026 | SCHEDULE 13D/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 |
| 03 Aug 2026 |
8-K: Other Events
On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the “Business”) to Par Health, Inc (“Par Health”). Consideration for the transaction is expected to t... |
| 23 Jul 2026 |
Form 4: Williamson Susan Ann, EVP & Chief Compliance Officer
Gave up 571 shares to cover exercise price or tax |
| 23 Jul 2026 |
Form 4: Basso Tracy, EVP & CHRO
Gave up 763 shares to cover exercise price or tax |
| 23 Jul 2026 |
Form 4: Stouch Cheryl Ann, EVP & Chief Info Officer
Gave up 328 shares to cover exercise price or tax |
| 17 Jul 2026 |
Form 4: Langlois Sophia J., Director
Granted 4,406 Restricted Stock Units |
| 17 Jul 2026 |
Form 4: Yoskowitz Marc J, Director
Granted 4,406 Restricted Stock Units |
| 17 Jul 2026 |
Form 4: Hirsch Scott, Director
Granted 4,406 Restricted Stock Units |
| 17 Jul 2026 |
Form 4: Zinman Jon, Director
Granted 4,406 Restricted Stock Units |
| 17 Jul 2026 |
Form 4: Efron Paul, Director
Granted 4,406 Restricted Stock Units |
| 17 Jul 2026 |
Form 4: Donato Leslie E, Director
Granted 4,406 Restricted Stock Units |
Loading...